Study on effectiveness of transfusion program in thalassemia major patients receiving multiple blood transfusions at a transfusion centre in Western India
Authors:
Open Access
- 1 January 2010
- journal article
- research article
- Published by Medknow in Asian Journal of Transfusion Science
- Vol. 4 (2) , 94-8
Abstract
Background : Children suffering from beta-thalassemia major require repeated blood transfusions which may be associated with dangers like iron overload and contraction of infections such as HIV, HCV, and HBsAg which ultimately curtail their life span. On the other hand, inadequate transfusions lead to severe anemia and general fatigue and debility. Materials and Methods: Data were obtained from 142 beta-thalassemia major patients aged 3 years or more receiving regular blood transfusions at a transfusion centre in Western India from 1 April 2009 to 30 June 2009. The clinical data and laboratory results were subsequently analyzed. Results: Of the 142 patients, 76 (53.5%) were undertransfused (mean Hb <10 gm%). 96 (67%) of the patients were taking some form of chelation therapy but out of them only 2 (2%) were adequately chelated (S. ferritin <1000 ng/ml). 5 (3.5%) of the patients were known diabetics on insulin therapy. 103 (72%) of the patients were retarded in terms of growth. The prevalence of transfusion-transmitted infections (TTIs) such as HCV, HIV, and HBsAg was respectively 45%, 2%, and 2%, with the prevalence of HCV being significantly more than the general population. The HCV prevalence showed positive correlation with the age of the patients and with the total no of blood transfusions received. As many as 15% (6 out of 40) children who were born on or after 2002 were HCV positive despite the blood they received being subjected to screening for HCV. Conclusions: The study suggests the need to step up the transfusions to achieve hemoglobin goal of 10 gm% (as per the moderate transfusion regimen) and also to institute urgent and effective chelation measures with the aim of keeping serum ferritin levels below 1000 ng/ml to avoid the systemic effects of iron overload. In addition, strict monitoring of the children for endocrinopathy and other systemic effects of iron overload should be done. Rigid implementation of quality control measures for the ELISA kits used to detect HCV in donor blood needs to be done urgently. Alternately, more sensitive and specific measures (like NAT testing) should be employed for detection of HCV. In the absence of a definitive cure accessible and available to all patients, strict implementation of the above suggested measures will go a long way in improving the quality (and quantity) of life in patients of beta-thalassemia major.Keywords
This publication has 10 references indexed in Scilit:
- Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overloadLeukemia Research, 2007
- Increased prevalence of iron‐overload associated endocrinopathy in thalassaemia versus sickle‐cell diseaseBritish Journal of Haematology, 2006
- Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patientsEuropean Journal of Haematology, 2005
- Complications of β-thalassemia major in North AmericaBlood, 2004
- Prevalence of hepatitis viruses among multi-transfused homogenous thalassaemia patientsHepatology Research, 2001
- A moderate transfusion regimen may reduce iron loading in beta‐ thalassemia major without producing excessive expansion of erythropoiesisTransfusion, 1997
- Prevalence of anti-HCV antibodies in western India.1995
- Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia MajorNew England Journal of Medicine, 1994
- Antibody to hepatitis-C virus in multi-transfused thalassaemics--Indian experience.1993
- Prevention of thalassemia: A necessity in IndiaIndian Journal of Pediatrics, 1992